Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Transition from fresh frozen plasma to solvent/detergent plasma in the Netherlands: comparing clinical use and transfusion reaction risks.

Saadah NH, Schipperus MR, Wiersum-Osselton JC, van Kraaij MG, Caram-Deelder C, Beckers EAM, Leyte A, Rondeel JMM, de Vooght KMK, Weerkamp F, Zwaginga JJ, van der Bom JG.

Haematologica. 2019 Jul 4. pii: haematol.2019.222083. doi: 10.3324/haematol.2019.222083. [Epub ahead of print]

2.

Age of platelet concentrates and time to the next transfusion.

Caram-Deelder C, van der Bom JG, Putter H, Leyte A, Kerkhof DV, Evers D, Beckers EA, Weerkamp F, Hudig F, Zwaginga JJ, Rondeel JMM, de Vooght KMK, Péquériaux NCV, Visser O, Wallis JP, Middelburg RA.

Transfusion. 2018 Jan;58(1):121-131. doi: 10.1111/trf.14388. Epub 2017 Oct 31.

PMID:
29090466
3.

Validation of multisource electronic health record data: an application to blood transfusion data.

Hoeven LRV, Bruijne MC, Kemper PF, Koopman MMW, Rondeel JMM, Leyte A, Koffijberg H, Janssen MP, Roes KCB.

BMC Med Inform Decis Mak. 2017 Jul 14;17(1):107. doi: 10.1186/s12911-017-0504-7.

4.

Storage time of platelet concentrates and all-cause bacteremia in hematologic patients.

Kreuger AL, Middelburg RA, Bank CMC, Beckers EAM, van Gammeren AJ, Leyte A, Rondeel JMM, de Vooght KMK, Weerkamp F, Zwaginga JJ, Kerkhoffs JLH, van der Bom JG.

Transfusion. 2017 Sep;57(9):2096-2103. doi: 10.1111/trf.14194. Epub 2017 Jun 26.

PMID:
28653425
5.

The Effect of Rosuvastatin on Markers of Immune Activation in Treatment-Naive Human Immunodeficiency Virus-Patients.

Weijma RG, Vos ER, Ten Oever J, Van Schilfgaarde M, Dijksman LM, Van Der Ven A, Van Den Berk GE, Brinkman K, Frissen JP, Leyte A, Schouten IW, Netea MG, Blok WL.

Open Forum Infect Dis. 2015 Dec 23;3(1):ofv201. doi: 10.1093/ofid/ofv201. eCollection 2016 Jan.

6.

A prospective randomised controlled trial to assess the efficacy of dynamic stabilisation of the lumbar spine with the Wallis ligament.

Marsh GD, Mahir S, Leyte A.

Eur Spine J. 2014 Oct;23(10):2156-60. doi: 10.1007/s00586-014-3487-4. Epub 2014 Jul 30.

PMID:
25073942
7.

Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate.

Dinkelaar J, Patiwael S, Harenberg J, Leyte A, Brinkman HJ.

Clin Chem Lab Med. 2014 Nov;52(11):1615-23. doi: 10.1515/cclm-2014-0307.

PMID:
24902009
8.

Haemolytic anaemia after nitrofurantoin treatment in a pregnant woman with G6PD deficiency.

van de Mheen L, Smits SM, Terpstra WE, Leyte A, Bekedam DJ, van den Akker ES.

BMJ Case Rep. 2014 Apr 30;2014. pii: bcr2013010087. doi: 10.1136/bcr-2013-010087.

9.

Clinical performance evaluation of the CellaVision Image Capture System in the white blood cell differential on peripheral blood smears.

Smits SM, Leyte A.

J Clin Pathol. 2014 Feb;67(2):168-72. doi: 10.1136/jclinpath-2013-201737. Epub 2013 Sep 16.

PMID:
24043716
10.

In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban.

Dinkelaar J, Molenaar PJ, Ninivaggi M, de Laat B, Brinkman HJ, Leyte A.

J Thromb Haemost. 2013 Jun;11(6):1111-8. doi: 10.1111/jth.12236.

11.

Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation.

Molenaar PJ, Dinkelaar J, Leyte A.

Clin Chem Lab Med. 2012 Oct 1;50(10):1799-807. doi: 10.1515/cclm-2012-0055.

PMID:
23089710
12.

Comparative study of blood collection tubes and thromboplastin reagents for correction of INR discrepancies: a proposal for maximum allowable magnesium contamination in sodium citrate anticoagulant solutions.

van den Besselaar AM, van Zanten AP, Brantjes HM, Elisen MG, van der Meer FJ, Poland DC, Sturk A, Leyte A, Castel A.

Am J Clin Pathol. 2012 Aug;138(2):248-54. doi: 10.1309/AJCPGSB5YPJRREEV.

PMID:
22904137
13.

Chronic renal failure is accompanied by endothelial activation and a large increase in microparticle numbers with reduced procoagulant capacity.

Trappenburg MC, van Schilfgaarde M, Frerichs FC, Spronk HM, ten Cate H, de Fijter CW, Terpstra WE, Leyte A.

Nephrol Dial Transplant. 2012 Apr;27(4):1446-53. doi: 10.1093/ndt/gfr474. Epub 2011 Aug 26.

PMID:
21873622
14.
15.

Elevated numbers and altered subsets of procoagulant microparticles in breast cancer patients using endocrine therapy.

Trappenburg MC, van Schilfgaarde M, Bredewold EO, van Aalderen MC, Spronk HM, Ten Cate H, Leyte A, Terpstra WE.

Thromb Res. 2011 Apr;127(4):363-9. doi: 10.1016/j.thromres.2010.12.015. Epub 2011 Jan 26.

PMID:
21272922
16.

Procoagulant myeloblast-derived microparticles in AML patients: changes in numbers and thrombin generation potential during chemotherapy.

Van Aalderen MC, Trappenburg MC, Van Schilfgaarde M, Molenaar PJ, Ten Cate H, Terpstra WE, Leyte A.

J Thromb Haemost. 2011 Jan;9(1):223-6. doi: 10.1111/j.1538-7836.2010.04133.x. No abstract available.

17.

Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates.

Oudemans-van Straaten HM, van Schilfgaarde M, Molenaar PJ, Wester JP, Leyte A.

Crit Care. 2009;13(6):R193. doi: 10.1186/cc8191. Epub 2009 Dec 3.

18.

Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia.

Trappenburg MC, van Schilfgaarde M, Marchetti M, Spronk HM, ten Cate H, Leyte A, Terpstra WE, Falanga A.

Haematologica. 2009 Jul;94(7):911-8. doi: 10.3324/haematol.13774. Epub 2009 Jun 8.

19.

Circulating white blood cells and platelets amplify oxidative stress in heart failure.

Ijsselmuiden AJ, Musters RJ, de Ruiter G, van Heerebeek L, Alderse-Baas F, van Schilfgaarde M, Leyte A, Tangelder GJ, Laarman GJ, Paulus WJ.

Nat Clin Pract Cardiovasc Med. 2008 Dec;5(12):811-20. doi: 10.1038/ncpcardio1364. Epub 2008 Oct 28.

PMID:
18957960
20.

Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill.

Wester JP, Leyte A, Oudemans-van Straaten HM, Bosman RJ, van der Spoel JI, Haak EA, Porcelijn L, Zandstra DF.

Neth J Med. 2007 Mar;65(3):101-8.

21.

Increased PAI-1 plasma levels and risk of death from dengue: no association with the 4G/5G promoter polymorphism.

Mairuhu AT, Setiati TE, Koraka P, Hack CE, Leyte A, Faradz SM, ten Cate H, Brandjes DP, Osterhaus AD, Reitsma PH, van Gorp EC.

Thromb J. 2005 Nov 7;3:17.

22.

Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes.

Sommeijer DW, Joop K, Leyte A, Reitsma PH, ten Cate H.

J Thromb Haemost. 2005 Jun;3(6):1168-71. No abstract available.

23.

Ferritin and serum transferrin receptor predict iron deficiency in anemic patients with rheumatoid arthritis.

Bultink IE, Lems WF, van de Stadt RJ, Dinant HJ, Leyte A, Park DS, de Koning MH, Dijkmans BA.

Arthritis Rheum. 2001 Apr;44(4):979-81. No abstract available.

24.

Automated, simultaneous detection of the factor V Leiden and prothrombin (G20210A) variants using multiplex PCR and a line probe assay.

Leyte A, Smits PH, van Straalen JP, van Doorn LJ, Quint WG.

Thromb Haemost. 2000 Feb;83(2):354-5. No abstract available.

PMID:
10739403
25.

Evaluation of the Hitachi 911 for routine urine analysis and for measurement of various special serum analytes.

van Straalen JP, Leyte A, Weber JA, Gorgels JP, Sanders GT.

Eur J Clin Chem Clin Biochem. 1995 May;33(5):315-22.

PMID:
7578611
26.

Biological activity of recombinant factor VIII variants lacking the central B-domain and the heavy-chain sequence Lys713-Arg740: discordant in vitro and in vivo activity.

Mertens K, Donath MJ, van Leen RW, de Keyzer-Nellen MJ, Verbeet MP, Klaasse Bos JM, Leyte A, van Mourik JA.

Br J Haematol. 1993 Sep;85(1):133-42.

PMID:
8251380
27.
28.

Trimeric G proteins and vesicle formation.

Barr FA, Leyte A, Huttner WB.

Trends Cell Biol. 1992 Apr;2(4):91-4.

PMID:
14732001
29.
30.

The pro-polypeptide of von Willebrand factor is required for the formation of a functional factor VIII-binding site on mature von Willebrand factor.

Leyte A, Voorberg J, Van Schijndel HB, Duim B, Pannekoek H, Van Mourik JA.

Biochem J. 1991 Feb 15;274 ( Pt 1):257-61.

31.

Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor.

Leyte A, van Schijndel HB, Niehrs C, Huttner WB, Verbeet MP, Mertens K, van Mourik JA.

J Biol Chem. 1991 Jan 15;266(2):740-6.

32.

Inhibition of human coagulation factor VIII by monoclonal antibodies. Mapping of functional epitopes with the use of recombinant factor VIII fragments.

Leyte A, Mertens K, Distel B, Evers RF, De Keyzer-Nellen MJ, Groenen-Van Dooren MM, De Bruin J, Pannekoek H, Van Mourik JA, Verbeet MP.

Biochem J. 1989 Oct 1;263(1):187-94.

33.

Supplemental Content

Support Center